# Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation

> **NCT05250362** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sichuan University** · enrollment: 56 (estimated)

## Conditions studied

- Hematologic Malignancy

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT05250362
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-01
- **Primary completion:** 2025-02-28
- **Final completion:** 2025-12-31
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2022-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05250362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05250362, "Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05250362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*